{ "docId": "019dd923-622c-750b-8b99-bca3fd68622d", "docSlug": "4c8fe6013c68", "documentTitle": "iRhythm Technologies, Inc. (IRTC)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-18 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 11, "pageCount": 101, "prevPage": 10, "nextPage": 12, "slideType": "problem_statement", "function": "diagnose_problem", "density": "dense", "nDataPoints": 3, "notes": "The slide uses a yellow callout box to emphasize the core thesis. It highlights a disconnect between company claims and actual physician sentiment.", "elementsJson": [ "headline_text", "callout_box", "paragraph" ], "metadataConfidence": 0.95, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/11", "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-11", "components": [ { "bbox": { "h": 0.03, "w": 0.96, "x": 0.02, "y": 0.78 }, "kind": "callout", "text": "We Question iRhythm’s Prospects for Continued High Growth and Improved Profitability", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "12ecf47b-aa05-4130-966b-f78b7ad6dc78", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.96, "x": 0.02, "y": 0.18 }, "kind": "callout", "text": "We Believe the Asymptomatic Market Opportunity Will Disappoint", "attrs": null, "subkind": "primary", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "630316d6-97eb-4936-8078-6611330a719b", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "callout", "text": "We believe the current market served by iRhythm products is quite small, between 4.5 to 6.5 million patients a year.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-0395-748f-9564-d42f6102d81d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.96, "x": 0.02, "y": 0.82 }, "kind": "paragraph", "text": "We acknowledge the market's reaction to iRhythm’s recent reported results, but we believe these results represent only transitory strength. We see numerous growth headwinds facing iRhythm. Q1 disclosure suggested that, absent referral activity from PCPs, YoY revenue growth was modest at best, and iRhythm failed to disclose the information needed to update this analysis. With increases in “non-contracted” revenue, contractual adjustments, and accounts receivable write-offs, we observe a marked decline in iRhythm’s reported revenue quality. We also believe it is possible that revenue has benefitted from inflated reimbursement", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "813837cd-de65-4cf2-b80f-862e6d8aa53c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.55, "w": 0.96, "x": 0.02, "y": 0.22 }, "kind": "paragraph", "text": "We believe the current market served by iRhythm products is quite small, between 4.5 to 6.5 million patients a year. Already having ~70% market share with its Zio XT/Monitor, iRhythm has had to find a new leg of growth to support its hefty valuation. The Company settled on the opportunity to have primary care physicians (PCPs) proactively prescribe monitors for asymptomatic patients, suggesting there is widespread support because (1) such pre-emptive monitoring can avoid more costly future medical interventions, and (2) doing so can relieve the burden on cardiologists. Of course, the Company excitedly pitches that the asymptomatic market could expand its addressable market by 27 million patients annually. Our research finds that such testing has not been adopted as a standard of care by any credible organization. Moreover, we found that cardiologists are not supportive of asymptomatic testing because they believe PCPs are not qualified to interpret the data. This highlights what we believe is a major disconnect in iRhythm’s strategy. In stark contrast to iRhythm’s claim of “99% physician agreement” with their final reports, our cardiologist survey found materially more frequent disagreements with final reports and a widespread distrust of supplier reports due to the errors made by supplier CCTs (error incidence that is supported by the FDA's findings). In addition, many of the cardiologists we surveyed also believe testing asymptomatic patients will inevitably result in over-testing while doing little to improve outcomes. Moreover, while iRhythm likes to point to the widespread prevalence of arrhythmias, we found that cardiologists believe monitoring is only justifiable when the patient diagnosis involves certain types of strokes, suggesting a much more limited patient population. We also question the ROI on asymptomatic monitoring, as most tests need to be repeated (in part due to PCP errors) and because of short patient coverage duration for a given insurer (making proactive intervention less economical). Insofar as a meaningful asymptomatic market develops, we believe it will be dominated by near-ubiquitous consumer devices. Apple and Samsung smartwatches have the ability to test for arrhythmias with near-comparable sensitivity and specificity at practically zero cost to insurers. We have seen this movie before. Apple is poised to disrupt the hearing aid market with its earbuds, and we expect the same here.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d7d8e91e-40c8-4955-b6d4-6e70e6ce2edd", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.31, "y": 0.05 }, "kind": "title", "text": "We Believe iRhythm’s Strategy Of Targeting Asymptomatic Patients Is Flawed", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f29ba1b6-f311-4702-a045-f25f7ff313bd", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "from": 8, "beatId": "98bf75b1-d631-41a2-8007-79b7391e3925", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Expose Contradiction", "beatSlug": null, "evidence": "The document presents various contradictions and concerns regarding iRhythm's products and practices.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "loops": [ { "to": 20, "from": 9, "name": "The Reveal", "slug": "05-the-reveal", "bestFor": "Product launches, strategic pivots, unexpected findings", "matchId": "8bdc237c-9f95-46ed-95d1-4a4201a5a71e", "evidence": "The document presents various concerns and criticisms of iRhythm.", "position": 0, "objective": "To reveal concerns about iRhythm's products and management practices", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "confidence": 0.7, "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }